Immunogenicity of a Live Dengue Vaccine (TAK-003)

被引：4

作者：

de Silva, Aravinda ^{[1
]}

White, Laura ^{[1
]}

机构：

[1] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 2022年 / 227卷 / 01期

关键词：

D O I：

10.1093/infdis/jiac424

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：163 / 164

页数：2

共 50 条

[21] VALIDATION OF A MICRONEUTRALIZATION TEST TO QUANTIFY DENGUE VIRUS NEUTRALIZING ANTIBODIES AFTER VACCINATION WITH THE TAK-003 TETRAVALENT DENGUE VACCINE CANDIDATE
Powell, Tim
Nanra, Jasdeep
Moss, Kelley
Green, Tina
Seaton, Brent
Dean, Hansi
Shaw, Eric
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 183 - 184
[22] Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination
Sirivichayakul, Chukiat
Biswal, Shibadas
Saez-Llorens, Xavier
Lopez-Medina, Eduardo
Borja-Tabora, Charissa
Bravo, Lulu
Kosalaraksa, Pope
Alera, Maria Theresa
Reynales, Humberto
Rivera, Luis
Watanaveeradej, Veerachai
Yu, Delia
Espinoza, Felix
Dietze, Reynaldo
Fernando, Lakkumar
Wickramasinghe, V. Pujitha
Moreira Jr, Edson Duarte
Fernando, Asvini D.
Gunasekera, Dulanie
Luz, Kleber
Venancio da Cunha, Rivaldo
Oliveira, Ana Lucia
Rauscher, Martina
Fan, Huihao
Borkowski, Astrid
Escudero, Ian
Tuboi, Suely
Lloyd, Eric
Tricou, Vianney
Folschweiller, Nicolas
Lefevre, Inge
Vargas, Luis Martinez
Wallace, Derek
JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (06): : e1214 - e1225
[23] Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial
Petri, Eckhardt
Biswal, Shibadas
Lloyd, Eric
Tricou, Vianney
Folschweiller, Nicolas
VACCINE, 2024, 42 (26)
[24] TAK-003 VACCINE-DRIVEN NEUTRALIZATION OF DIVERSE DENGUE GENOTYPES CIRCULATING IN ASIA PACIFIC AND LATIN AMERICA REGIONS
Karwal, Lovkesh
Kaiser, Maima
Bohning, Kelly
Zahralban-Steele, Melissa
Nascimento, Eduardo J.
DeMaso, Christina
Baldwin, Whitney
Fernandez, Stefan
Sharma, Mayuri
Dean, Hansi
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 51 - 51
[25] Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study
Tricou, Vianney
Essink, Brandon
Ervin, John E.
Turner, Mark
Escudero, Ian
Rauscher, Martina
Brose, Manja
Lefevre, Inge
Borkowski, Astrid
Wallace, Derek
PLOS NEGLECTED TROPICAL DISEASES, 2023, 17 (03):
[26] TAK003 dengue vaccine: A promising tool for dengue control
Nitika, Nitika
Bharti, Praveen K.
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2024, 17 (11) : 477 - 478
[27] PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF A NEW DENGUE VACCINE (TAK-003) IN A LARGE CATCH-UP COHORT IN PUERTO RICO
Shen, J.
Zerda, I
Hanley, R.
Kharitonova, E.
Janusz, Z.
Biswal, S.
Sharma, M.
Tricou, V
Kastner, R.
Wallace, D.
Rosas, A.
VALUE IN HEALTH, 2024, 27 (06) : S66 - S66
[28] GRADE 3 SOLICITED AND UNSOLICITED ADVERSE EVENTS (AES) FOLLOWING VACCINATION WITH TAKEDA'S TETRAVALENT DENGUE VACCINE CANDIDATE (TAK-003)
Ismail, E.
Tricou, V.
Folschweiller, N.
Lloyd, E.
Rauscher, M.
Biswal, S.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S105 - S105
[29] Travel medicine providers' opinions on the dengue vaccine TAK-003 as a travel vaccine and the need for decision-support information and materials before its launch in Japan
Fukunishi, Atsuko
Machida, Masaki
Fukushima, Shinji
Inoue, Shigeru
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
[30] An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life
Patel, Sanjay S.
Winkle, Peter
Faccin, Alice
Nordio, Francesco
LeFevre, Inge
Tsoukas, Claudia Galindo
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (02)

← 1 2 3 4 5 →